Onlit IV Injection

About Onlit IV 8 mg/4 ml Injection

Onlit IV is an anti-emetic injection that helps control nausea and vomiting. It contains ondansetron, which blocks the body's vomiting signals. It is given by a healthcare professional, and the doctor decides the dose and course.

There are 74 brands of Ondansetron listed in Bangladesh. 26 of them have a lower unit price than Onlit IV. The lowest listed price is Periset 16 mg Suppository at ৳ 1 per unit.

What is Onlit IV 8 mg/4 ml Injection?

Onlit IV is an injection that belongs to a group of medicines called anti-emetics, which are used to prevent and treat nausea and vomiting. Its active ingredient is ondansetron. Ondansetron works by blocking a specific receptor in the body that helps trigger the vomiting reflex, so signals that would normally cause nausea and vomiting are reduced. Onlit IV comes as an 8 mg/4 ml injection and is given by a healthcare professional. It is used in situations such as nausea and vomiting after surgery, or those caused by cancer chemotherapy or radiotherapy. The doctor decides the dose and course.

Uses of Onlit IV

Onlit IV is used to prevent and treat nausea and vomiting linked to certain medical treatments and situations. It can be given to help prevent nausea and vomiting caused by cancer chemotherapy, including repeated courses. It is also used to prevent and treat nausea and vomiting after surgery, and to prevent nausea and vomiting caused by radiotherapy. It is given by a healthcare professional. Ask the doctor for details about your own treatment.

How to use Onlit IV

Onlit IV is an injection, so it is given by a healthcare professional, usually in a hospital or clinic. It is not for you to inject yourself. The doctor decides the dose, how it is given and how long the course lasts, based on your condition. Tell the doctor about any medicines you take and any allergies you have before it is given. If you have questions about your treatment, ask your doctor or pharmacist.

Side effects of Onlit IV

Some people may notice side effects after receiving Onlit IV. Commonly reported ones include headache, constipation and diarrhoea, and most of these are mild or moderate. Rash, a feeling of flushing or warmth, hiccups and changes in liver enzymes have also been reported. Rarely, serious reactions such as allergic reactions, breathing difficulty, fast heartbeat, chest pain, low potassium and shortness of breath have been reported. Tell your doctor or nurse promptly if you feel unwell after the injection.

Safety and precautions

Tell the doctor before receiving Onlit IV if you have had an allergic reaction to ondansetron or to other similar anti-emetic medicines. It should not be used together with apomorphine. It is not a medicine that stimulates gut movement and is not a substitute for other treatments your doctor advises. In people who have had abdominal surgery, or with chemotherapy-related nausea, it may hide signs of a bowel problem, so the doctor will monitor you. There are no adequate, well-controlled studies in pregnant women, so ask your doctor if you are pregnant, planning pregnancy or breastfeeding. The doctor will decide whether it is suitable for you.

Frequently asked questions

What does the generic name ondansetron mean?

Ondansetron is the generic name of the active ingredient in Onlit IV. It is the standard name used for this medicine, while Onlit IV is the brand name given by its manufacturer. Knowing the generic name helps you and your pharmacist identify the medicine.

What is Onlit IV used for and what kind of medicine is it?

Onlit IV is an anti-emetic medicine. It is used to prevent and treat nausea and vomiting, including those caused by cancer chemotherapy or radiotherapy, and nausea and vomiting after surgery. It is given as an injection by a healthcare professional.

How is Onlit IV taken?

Onlit IV is an injection given by a healthcare professional, usually in a hospital or clinic. It is not self-administered. The doctor decides the dose, how it is given and the length of the course for your condition. Ask your doctor or pharmacist if you have questions.

Who should ask a doctor before receiving Onlit IV?

Ask the doctor first if you have had an allergic reaction to ondansetron or similar medicines, or if you are pregnant, planning pregnancy or breastfeeding. Also tell the doctor about other medicines you take, including apomorphine, and about any surgery you have had.

Indications

Ondansetron is a serotonin subtype 3 (5-HT3) receptor antagonist indicated:
  • Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.
  • Prevention and treatment of post-operative nausea and vomiting.
  • Prevention of radiotherapy-induced nausea and vomiting.

Pharmacology

Ondansetron is a potent, highly selective 5HT3 receptor-antagonist. Its precise mode of action in the control of nausea and vomiting is not known. Chemotherapeutic agents and radiotherapy may cause release of 5HT in the small intestine initiating a vomiting reflex by activating vagal afferents via 5HT3 receptors. Ondansetron blocks the initiation of this reflex. Activation of vagal afferents may also cause a release of 5HT in the area postrema, located on the floor of the fourth ventricle, and this may also promote emesis through a central mechanism. Thus, the effect of ondansetron in the management of the nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy is probably due to antagonism of 5HT3 receptors on neurons located both in the peripheral and central nervous system. The mechanisms of action in post-operative nausea and vomiting are not known but there may be common pathways with cytotoxic induced nausea and vomiting.

Dosage & Administration

Chemotherapy-Induced Nausea and Vomiting-
Adults, Pediatric patients (6 months to 18 years):
  • 8 mg tablet/orodispersible tablet: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose.
  • 4 mg orodispersible tablet: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose.
  • Injection: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose, infused intravenously over 15 minutes.
Radiotherapy-Induced Nausea and Vomiting-
Adults:
  • 8 mg tablet/orodispersible tablet: Initial Dose: 8 mg orally 1 to 2 hours before radiotherapy. Post Radiotherapy: 8 mg orally every 8 hours for up to 5 days after a course of treatment.
  • 4 mg orodispersible tablet: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose.
  • Injection: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose, infused intravenously over 15 minutes.
Postoperative Nausea and Vomiting-
Adults:
  • 8 mg tablet/orodispersible tablet: 16 mg given as two 8 mg tablets
  • 4 mg orodispersible tablet: 16 mg
  • Injection: 4 mg
Pediatrics (>40 kg): Injection: 4 mg
Pediatrics (40 kg): Injection: 0.1 mg/kg

Chemotherapy-induced Nausea and Vomiting-
Adults/Geriatric/Child of 12 years or over:
  • Highly emetogenic cancer chemotherapy: 30 ml (24 mg) Ondansetron Oral Solution administered 30 minutes before start of emetogenic chemotherapy.
  • Moderate emetogenic cancer chemotherapy: 10 ml (8 mg) Ondansetron Oral Solution administered 30 minutes before start of emetogenic chemotherapy. A further 10 ml dose should be administered after 8 hours of the first dose. One 10 ml dose should be administered twice a day (every 12 hours) for 1-2 days after completion of chemotherapy.
Pediatric (4-11 years): 5 ml (4 mg) Ondansetron Oral Solution should be taken 30 minutes before the start of chemotherapy. The other 2 doses should be taken 4 and 8 hours after the first dose. Then 5 ml oral solution should be administered 3 times a day (every 8 hours) for 1-2 days after completion of chemotherapy.


Oral solution:

Radiotherapy induced Nausea and Vomiting (Adults/Geriatric/Child of 12 years or over):
  • The recommended oral dosage: 10 ml (8 mg) Ondansetron Oral Solution 3 times daily.
  • For total body irradiation: 10 ml (8-mg) Ondansetron Oral Solution should be administered 1 to 2 hours before each fraction of radiotherapy administered each day.
  • For single high-dose fraction radiotherapy to the abdomen: one 10 ml Ondansetron Oral Solution should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy.
  • For daily fractionated radiotherapy to the abdomen: 10 ml (8-mg) Ondansetron Oral Solution should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for each day radiotherapy is given.
Postoperative Nausea and Vomiting (Adults/Geriatric/Child of 12 years or over):
  • 20 ml (16 mg) Ondansetron Oral Solution 1 hour before induction of anesthesia


Oral Soluble Film:

Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy:
  • Adult oral dose: 24 mg given successively as three 8 mg films 30 minutes before the start of chemotherapy.
Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy:
  • Adults and pediatric patients 12 years of age and older: One 8 mg film 30 minutes before chemotherapy followed by an 8 mg dose 8 hours later. Administer one 8 mg film twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy.
  • Pediatric patients 4 through 11 years of age: One 4 mg film three times a day. Administer the first dose 30 minutes before chemotherapy, with subsequent doses 4 and 8 hours later. Administer one 4 mg film three times a day (every 8 hours) for 1 to 2 days after completion of chemotherapy.
  • Prevention of nausea and vomiting associated with radiotherapy: The adult dosage is one 8 mg film three times a day.
  • Postoperative nausea and vomiting: The adult dose is 16 mg given successively as two 8 mg films 1 hour before anesthesia.

Interaction

Ondansetron does not itself appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the liver. Because Ondansetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes, inducers or inhibitors of these enzymes may change the clearance and hence, the half-life of Ondansetron. On the basis of available data, no dosage adjustment of Ondasetron is recommended for patients on these drugs.

Contraindications

Contraindicated in patients known to have hypersensitivity to the drug or any of its components. Concomitant use of apomorphine.

Side Effects

Frequently reported adverse events were headache, constipation and diarrhea, but the majority have been mild or moderate in nature. In chemotherapy-induced nausea and vomiting, rash has occurred in approximately 1% of patients receiving Ondansetron. There also have been reports to a sensation of flushing or warmth, hiccups and liver enzyme abnormalities. Rare cases of anaphylaxis, brochospasm, tachycardia, angina (chest pain), hypokalemia, shortness of breath have also been reported, except for bronchospasm and anaphylaxis, the relationship to Ondansetron is unclear. There have been no evidence to extrapyramidal reactions, in rare case oculogyric crisis appearing alone, as well as with other dystonic reactions without definitive clinical evidence. In case of PONV, with the exception of headache, rates of these events were not significantly different in the Ondansetron and placebo groups.

Pregnancy & Lactation

Carcinogenic effects were not seen in 2-year studies in rats and mice with oral Ondansetron doses up to 10 and 30 mg/kg per day, respectively. Ondansetron was not mutagenic in standard tests for mutagenicity. Oral administration of Ondansetron up to 15 mg/kg per day did not affect fertility or general reproduction performance of male and female rats.

Reproduction studies have been performed in pregnant rats and rabbits at daily oral doses up to 15 and 30 mg/kg per day, respectively, and have revealed no evidence of impaired fertility or harm to the fetus due to Ondansetron. There are, however, no adequate and well-controlled studies in pregnant women. Ondansetron is excreted in the breast milk of rats. So caution should be exercised when Ondansetron is administered to a nursing women.

Precautions & Warnings

Hypersensitivity reactions have been reported in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists. Ondansetron is not a drug that stimulates gastric or intestinal peristalsis. It should not be used instead of nasogastric suction. The use of Ondansetron in patients following abdominal surgery or in patients with chemotherapy-induced nausea and vomiting may mask a progressive ileus and/or gastric distension.

Storage Conditions

Store at temperature not exceeding 30ºC in a dry place. Protect from light and moisture.

Alternative brands of Ondansetron

Other brands with the same generic name, cheapest first.

Periset Suppository

16 mg

Ondansetron

The ACME Laboratories Ltd.

৳ 0.98 ৳ 1 2% off per unit

Oncodex Tablet

4 mg

Ondansetron

Jayson Pharmaceuticals Ltd.

৳ 4.44 ৳ 4.53 2% off per unit

Seton Tablet

4 mg

Ondansetron

Delta Pharma Limited

৳ 4.9 ৳ 5.00 2% off per unit

Seton Tablet

8 mg

Ondansetron

Delta Pharma Limited

৳ 4.9 ৳ 5.00 2% off per unit

Oncodex Tablet

8 mg

Ondansetron

Jayson Pharmaceuticals Ltd.

৳ 7.9 ৳ 8.06 2% off per unit

Emiteron Tablet

8 mg

Ondansetron

Premier Pharmaceuticals Ltd.

৳ 8.82 ৳ 9.00 2% off per unit

Periset Tablet

8 mg

Ondansetron

The ACME Laboratories Ltd.

৳ 9.83 ৳ 10.03 2% off per unit

Osetron Tablet

8 mg

Ondansetron

Advanced Chemical Industries PLC

৳ 9.87 ৳ 10.07 2% off per unit

See all 74 brands

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.